Request Demo
Last update 07 Jun 2025
Anti-TnMUC-1 CAR-T cell therapy (Tmunity Therapeutics)
Last update 07 Jun 2025
Overview
Basic Info
Drug Type CAR-T |
Synonyms AntiTnMUC1 CAR T cell therapy Tmunity Therapeutics, TmTNMUC 01 CART, TnMUC1 CART |
Target |
Action inhibitors |
Mechanism MUC1 inhibitors(Mucin-1 inhibitors), Gene transference(Gene transference), T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with Anti-TnMUC-1 CAR-T cell therapy (Tmunity Therapeutics)NCT04025216
A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
100 Clinical Results associated with Anti-TnMUC-1 CAR-T cell therapy (Tmunity Therapeutics)
Login to view more data
100 Translational Medicine associated with Anti-TnMUC-1 CAR-T cell therapy (Tmunity Therapeutics)
Login to view more data
100 Patents (Medical) associated with Anti-TnMUC-1 CAR-T cell therapy (Tmunity Therapeutics)
Login to view more data
100 Deals associated with Anti-TnMUC-1 CAR-T cell therapy (Tmunity Therapeutics)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Fallopian Tube Carcinoma | Phase 1 | United States | 10 Oct 2019 | |
| Multiple Myeloma | Phase 1 | United States | 10 Oct 2019 | |
| Non-Small Cell Lung Cancer | Phase 1 | United States | 10 Oct 2019 | |
| Ovarian Cancer | Phase 1 | United States | 10 Oct 2019 | |
| Pancreatic Ductal Adenocarcinoma | Phase 1 | United States | 10 Oct 2019 | |
| Triple Negative Breast Cancer | Phase 1 | United States | 10 Oct 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | MUC1 positive Solid Tumors MUC1 Positive | 6 | TnMUC1 (Cohort 1 (no lymphodepletion)) | koeowjbnnf(pbjrazqswn) = The most common AE’s were low-grade GI symptoms (e.g., nausea, abdominal pain) in 5/6 patients (83.3%), generalized disorders (e.g., chills, fatigue) in 5/6 (83.3%) and hematologic disorders (e.g., anemia, neutropenia) in 3/6 (50%) of patients. bapfpybohh (oulgvtcpwl ) View more | Positive | 28 May 2021 | |
TnMUC1 (Cohort 2 (flu/cy lymphodepletion)) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free